TapewireFind a company

person · Reporting owner

PFENNIGER RICHARD C JR

Disclosed activity across 8 companies

Tapewire entity
36007
SEC CIK
0001200796

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BioCardia, Inc.BCDA;BCDAW · Entity 7752DirectorDecember 31, 2020January 06, 2021
Cocrystal Pharma, Inc.COCP · Entity 7621DirectorJanuary 09, 2026January 13, 2026
Fluent, Inc.FLNT · Entity 6736DirectorJune 17, 2026June 18, 2026
GP STRATEGIES CORPGPX · Entity 134545DirectorOctober 14, 2021October 18, 2021
GeneDx Holdings Corp.WGS · Entity 1634DirectorJune 18, 2026June 23, 2026
OPKO HEALTH, INC.OPK · Entity 4891DirectorJune 18, 2026June 22, 2026
Wright Investors Service Holdings, Inc.WISH · Entity 8388DirectorOctober 22, 2018October 22, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BioCardia, Inc.

Report date December 31, 2020 · Filed January 06, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect51,970 Ending reported balance After 2020-12-31 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2020-12-31 · Grant · Acquired 2,800 · Balance 48,845

F1: The award relates to vested restricted stock units ("RSUs") granted December 31, 2020, each of which represents a contingent right to receive one share of the Issuer's common stock, but for which delivery of common stock will occur the earliest of (1) the two (2) year anniversary of the grant date; (3) the Reporting Person's separation from service; (3) a change in control, as defined in the Issuer's 2016 Equity Incentive Plan; or (4) the Reporting Person's death.

Row 2 · 2020-12-31 · Grant · Acquired 3,125 · Balance 51,970

F1: The award relates to vested restricted stock units ("RSUs") granted December 31, 2020, each of which represents a contingent right to receive one share of the Issuer's common stock, but for which delivery of common stock will occur the earliest of (1) the two (2) year anniversary of the grant date; (3) the Reporting Person's separation from service; (3) a change in control, as defined in the Issuer's 2016 Equity Incentive Plan; or (4) the Reporting Person's death.

Filing footnotes · ownership attribution and instrument terms

F1: The award relates to vested restricted stock units ("RSUs") granted December 31, 2020, each of which represents a contingent right to receive one share of the Issuer's common stock, but for which delivery of common stock will occur the earliest of (1) the two (2) year anniversary of the grant date; (3) the Reporting Person's separation from service; (3) a change in control, as defined in the Issuer's 2016 Equity Incentive Plan; or (4) the Reporting Person's death.

Cocrystal Pharma, Inc.

Report date January 09, 2026 · Filed January 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09Direct16,410 Reported balance After 2026-01-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-09 · Grant · Acquired 16,410 · Balance 16,410

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Fluent, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect120,438 Reported balance After 2026-06-17 transaction · row 1
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 30,096 · Balance 120,438

F1: On June 17, 2026, the Reporting Person received a grant of 30,096 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. The RSUs will vest in three equal annual installments, with the first installment vesting on June 17, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: On June 17, 2026, the Reporting Person received a grant of 30,096 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. The RSUs will vest in three equal annual installments, with the first installment vesting on June 17, 2027.

GP STRATEGIES CORP

Report date October 14, 2021 · Filed October 18, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2021-10-14 transaction · row 1
1 source row

Row 1 · 2021-10-14 · Disposition to issuer · Disposed 56,297 · Balance 0

F1: On July 15, 2021, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Learning Technologies Group plc, a public limited company incorporated in England and Wales ("LTG"), Learning Technologies Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of LTG ("US Holdco"), and Gravity Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of US Holdco ("Merger Sub"), pursuant to which each share of common stock of the Issuer was converted into the right to receive a cash payment equal to the per share merger consideration of $20.85.

Filing footnotes · ownership attribution and instrument terms

F1: On July 15, 2021, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Learning Technologies Group plc, a public limited company incorporated in England and Wales ("LTG"), Learning Technologies Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of LTG ("US Holdco"), and Gravity Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of US Holdco ("Merger Sub"), pursuant to which each share of common stock of the Issuer was converted into the right to receive a cash payment equal to the per share merger consideration of $20.85.

GeneDx Holdings Corp.

Report date June 18, 2026 · Filed June 23, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect45,082 Reported balance After 2026-06-18 transaction · row 1
1 source row

Row 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 45,082

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect4,248 Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

OPKO HEALTH, INC.

Report date June 18, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2036-06-17Direct60,000 Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-18 · Grant · Acquired 60,000 · Balance 60,000

Wright Investors Service Holdings, Inc.

Report date October 22, 2018 · Filed October 22, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common stockSEC Table I · non-derivativeDirect458,971 Reported balance After 2018-10-22 transaction · row 1
1 source row

Row 1 · 2018-10-22 · Grant · Acquired 20,313 · Balance 458,971

F1: Quarterly director's fee for the fourth fiscal quarter of 2018.

F2: Closing price of Wright Investors' Service Holdings, Inc. common stock on September 30, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Quarterly director's fee for the fourth fiscal quarter of 2018.

F2: Closing price of Wright Investors' Service Holdings, Inc. common stock on September 30, 2018.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ASENSUS SURGICAL, INC.

Report date August 22, 2024 · Filed August 22, 2024

Section 16 reporting ended · disclosed 2024-08-22. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-08-22 transaction · row 1
1 source row

Row 1 · 2024-08-22 · Disposition to issuer · Disposed 189,417 · Balance 0

F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 18, 2026 Filed Jun 22, 2026 21:34 UTC OPKO HEALTH, INC. OPK · Entity 4891 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001193125-26-277740 · ownership.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-06-17

Read SEC document
June 18, 2026 Filed Jun 23, 2026 20:29 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 3,576 $0.00 $0.00
Disclosure

SEC source: 0001200796-26-000002 · form4-06232026_080619.xml · derivative · entry 3

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 3,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

F3 · derivative.expiration_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 20:29 UTC GeneDx Holdings Corp. WGS · Entity 1634 GrantRestricted Stock Unit · Derivative 4,248 $0.00 $0.00
Disclosure

SEC source: 0001200796-26-000002 · form4-06232026_080619.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,248

Underlying: Class A Common Stock · 4,248 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

F2 · derivative.expiration_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 20:29 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 3,576 $0.00 $0.00
Disclosure

SEC source: 0001200796-26-000002 · form4-06232026_080619.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
June 17, 2026 Filed Jun 18, 2026 20:33 UTC Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 30,096 $0.00 $0.00
Disclosure

SEC source: 0001437749-26-021167 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,438

F1 · shares: On June 17, 2026, the Reporting Person received a grant of 30,096 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. The RSUs will vest in three equal annual installments, with the first installment vesting on June 17, 2027.

Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:10 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantStock Options (Right to Buy) · Derivative 16,410 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0001493152-26-002042 · ownership.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,410

Underlying: Common Stock · 16,410 shares

Expires 2036-01-09

F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:15 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantWarrants · Derivative 40,000 $1.39 Strike: $1.24 $55,600.00
Disclosure

SEC source: 0001493152-25-020219 · ownership.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-01-28

F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

F1 · derivative.exercise_date: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:15 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantCommon Stock 20,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001493152-25-020219 · ownership.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,400

F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

F1 · price: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

F2 · balance_after: Includes shares of common stock issuable upon vesting of restricted stock units.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:45 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 12,924 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-017988 · form4-06232025_090603.xml · derivative · entry 3

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 12,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:45 UTC GeneDx Holdings Corp. WGS · Entity 1634 GrantRestricted Stock Unit · Derivative 3,576 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-017988 · form4-06232025_090603.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,576

Underlying: Class A Common Stock · 3,576 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:45 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 12,924 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-017988 · form4-06232025_090603.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:43 UTC Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 39,682 $0.00 $0.00
Disclosure

SEC source: 0001437749-25-021055 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,341

F1 · shares: On June 18, 2025, the Reporting Person received a grant of 39,682 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. These RSUs will vest in three equal annual installments, beginning on June 18, 2026.

Read SEC document
May 02, 2025 Filed May 5, 2025 20:48 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 918 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011978 · form4-05052025_080539.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 918 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: 1/3 of the total RSUs shall vest annually of the total RSUs monthly annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F2 · derivative.expiration_date: 1/3 of the total RSUs shall vest annually of the total RSUs monthly annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document
May 02, 2025 Filed May 5, 2025 20:48 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 918 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011978 · form4-05052025_080539.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
April 23, 2025 Filed Apr 23, 2025 21:12 UTC OPKO HEALTH, INC. OPK · Entity 4891 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $1.47 $0.00
Disclosure

SEC source: 0000950170-25-057518 · ownership.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-04-22

Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:05 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantCommon Stock 8,067 Not disclosed Not disclosed
Disclosure

SEC source: 0001493152-24-040902 · ownership.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,400

F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan.

F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan.

Read SEC document
August 22, 2024 Filed Aug 22, 2024 09:12 UTC ASENSUS SURGICAL, INC. ASXC · Entity 88098 Disposition to issuerCommon Stock 189,417 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-24-027545 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.

Read SEC document
June 26, 2024 Filed Jun 27, 2024 20:16 UTC GeneDx Holdings Corp. WGS · Entity 1634 GrantRestricted Stock Unit · Derivative 12,924 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-018330 · form4-06272024_080621.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,924

Underlying: Class A Common Stock · 12,924 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
June 20, 2024 Filed Jun 24, 2024 21:41 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 5,828 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-018044 · form4-06242024_090654.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 5,828 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
June 20, 2024 Filed Jun 24, 2024 21:41 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 5,828 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-018044 · form4-06242024_090654.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
June 05, 2024 Filed Jul 2, 2024 14:15 UTC Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 21,429 $0.00 $0.00
Disclosure

SEC source: 0001437749-24-021888 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,659

F1 · shares: On April 11, 2024, the Issuer effected a 6-for-1 reverse stock split (the "Reverse Stock Split"). The holding reported here reflects the Reverse Stock Split.

F2 · shares: On June 5, 2024, the Reporting Person received a grant of 21,429 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. These RSUs will vest in three equal annual installments, beginning on June 1, 2025.

Read SEC document
June 04, 2024 Filed Jun 18, 2026 20:31 UTC Amendment Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 21,429 $0.00 $0.00
Disclosure

SEC source: 0001437749-26-021163 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,660

F1 · balance_after: On June 5, 2024, the Reporting Person filed a Form 4 which inadvertently reported, that following his activity, the Reporting Person owned a total of 50,659 shares of common stock which amount did not accurately reflect the total impact for Issuer's 1-for-6 reverse stock split effectuated on April 11, 2024. As reported in this amendment, following the activity, the Reporting Person owned 50,660 shares of common stock.

Read SEC document
May 02, 2024 Filed May 3, 2024 20:04 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 918 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-012143 · form4-05032024_080531.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 918

Underlying: Class A Common Stock · 918 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: 1/3 of the total RSUs shall vest annually of the total RSUs monthly annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F2 · derivative.expiration_date: 1/3 of the total RSUs shall vest annually of the total RSUs monthly annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document
May 02, 2024 Filed May 3, 2024 20:04 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 918 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-012143 · form4-05032024_080531.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,836

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
January 05, 2024 Filed Jan 5, 2024 17:42 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 12,000 $0.95 $11,385.60
Disclosure

SEC source: 0000950170-24-002345 · ownership.xml · nonDerivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,000

Read SEC document
January 05, 2024 Filed Jan 5, 2024 17:42 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 13,000 $0.93 $12,043.20
Disclosure

SEC source: 0000950170-24-002345 · ownership.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,000

Read SEC document
November 13, 2023 Filed Nov 14, 2023 12:10 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 10,000 $1.30 $12,999.00
Disclosure

SEC source: 0001209191-23-055105 · doc4.xml · nonDerivative · entry 4

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Read SEC document
November 13, 2023 Filed Nov 14, 2023 12:10 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 5,000 $1.30 $6,498.50
Disclosure

SEC source: 0001209191-23-055105 · doc4.xml · nonDerivative · entry 3

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,000

Read SEC document
November 13, 2023 Filed Nov 14, 2023 12:10 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 5,000 $1.30 $6,497.00
Disclosure

SEC source: 0001209191-23-055105 · doc4.xml · nonDerivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 285,000

Read SEC document
November 13, 2023 Filed Nov 14, 2023 12:10 UTC OPKO HEALTH, INC. OPK · Entity 4891 PurchaseCommon Stock 5,000 $1.30 $6,496.50
Disclosure

SEC source: 0001209191-23-055105 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 280,000

Read SEC document
November 08, 2023 Filed Nov 9, 2023 00:19 UTC GeneDx Holdings Corp. WGS · Entity 1634 PurchaseClass A Common Stock 10,000 $1.49 $14,889.00
Disclosure

SEC source: 0001209191-23-054765 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,918

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.5166, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 21:10 UTC GeneDx Holdings Corp. WGS · Entity 1634 PurchaseClass A Common Stock 5,000 $5.10 $25,523.00
Disclosure

SEC source: 0001209191-23-046599 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,918

Read SEC document
July 21, 2023 Filed Jul 25, 2023 20:20 UTC GeneDx Holdings Corp. WGS · Entity 1634 GrantRestricted Stock Unit · Derivative 5,828 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043299 · doc4.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,828

Underlying: Class A Common Stock · 5,828 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 20:20 UTC GeneDx Holdings Corp. WGS · Entity 1634 GrantStock Option (Right to Buy) · Derivative 8,816 $0.00 Strike: $7.89 $0.00
Disclosure

SEC source: 0001209191-23-043299 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,816

Underlying: Class A Common Stock · 8,816 shares

Expires 2033-07-20

F1 · derivative.exercise_date: The stock option shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:05 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantStock Options (Right to Buy) · Derivative 7,333 $0.00 Strike: $2.67 $0.00
Disclosure

SEC source: 0001493152-23-025081 · ownership.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,333

Underlying: Common Stock · 7,333 shares

Expires 2033-07-18

F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date.

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:17 UTC OPKO HEALTH, INC. OPK · Entity 4891 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039363 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-06-21

Read SEC document
June 07, 2023 Filed Jun 15, 2023 01:58 UTC Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 115,385 $0.00 $0.00
Disclosure

SEC source: 0001437749-23-017501 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,385

F1 · shares: On June 7, 2023, the Reporting Person received a grant of 115,385 Restricted Stock Units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. These RSUs vest in three equal annual installments beginning on June 1, 2024.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 17:06 UTC ASENSUS SURGICAL, INC. ASXC · Entity 88098 GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-035502 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,417

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2024 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · price: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2024 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

Read SEC document
May 18, 2023 Filed May 22, 2023 20:59 UTC GeneDx Holdings Corp. WGS · Entity 1634 PurchaseClass A Common Stock 5,000 $5.90 $29,499.50
Disclosure

SEC source: 0001209191-23-031499 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,918

Read SEC document
May 02, 2023 Filed May 4, 2023 20:11 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 30,303 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027332 · doc4.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 60,606 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The underlying shares vest as to 1/3 of the total award annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date.

F2 · derivative.expiration_date: The underlying shares vest as to 1/3 of the total award annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date.

Read SEC document
May 02, 2023 Filed May 4, 2023 20:11 UTC GeneDx Holdings Corp. WGS · Entity 1634 Exercise / conversionClass A Common Stock 30,303 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027332 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,303

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 06, 2022 Filed Oct 12, 2022 20:42 UTC Fluent, Inc. FLNT · Entity 6736 GrantCommon Stock 60,000 $0.00 $0.00
Disclosure

SEC source: 0001437749-22-024031 · rdgdoc.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: On October 6, 2022, the Reporting Person received a grant of 60,000 restricted stock units ("RSUs") under the Issuer's 2022 Omnibus Equity Incentive Plan. The RSUs will vest in three equal annual installments beginning on October 1, 2023.

Read SEC document
July 25, 2022 Filed Aug 3, 2022 20:03 UTC Cocrystal Pharma, Inc. COCP · Entity 7621 GrantStock Options (Right to Buy) · Derivative 80,000 $0.00 Strike: $0.42 $0.00
Disclosure

SEC source: 0001493152-22-021151 · ownership.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-07-25

F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date.

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:29 UTC OPKO HEALTH, INC. OPK · Entity 4891 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042280 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2032-07-13

Read SEC document
June 14, 2022 Filed Jun 15, 2022 19:38 UTC ASENSUS SURGICAL, INC. ASXC · Entity 88098 GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037127 · doc4.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,417

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2023 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · price: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2023 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

Read SEC document
May 02, 2022 Filed May 5, 2022 00:36 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantRestricted Stock Unit · Derivative 90,909 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-027291 · doc4.xml · derivative · entry 2

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,909

Underlying: Class A Common Stock · 90,909 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The restricted stock units vests as of 1/3 of the total units annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The restricted stock units vests as of 1/3 of the total units annually beginning on May 2, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 02, 2022 Filed May 5, 2022 00:36 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantStock Option (Right to Buy) · Derivative 157,828 $0.00 Strike: $2.16 $0.00
Disclosure

SEC source: 0001209191-22-027291 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,828

Underlying: Class A Common Stock · 157,828 shares

Expires 2032-05-01

F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on June 2, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 02, 2022 Filed May 6, 2022 23:05 UTC Amendment GeneDx Holdings Corp. SMFR · Entity 1634 GrantStock Option · Derivative 157,828 $0.00 Strike: $2.20 $0.00
Disclosure

SEC source: 0001209191-22-027694 · doc4a.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,828

Underlying: Class A Common Stock · 157,828 shares

Expires 2032-05-01

F1 · derivative.exercise_price: This Form 4 amendment has been filed solely to correct the exercise price of a previously issued stock option to purchase shares of Class A Common Stock of the Issuer reported in a Form 4 filed on May 4, 2022 (the "Form 4"). The exercise price was inadvertently stated as $2.155 in the Form 4. The exercise price should have been stated as $2.20 in the Form 4.

F2 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on June 2, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
October 14, 2021 Filed Oct 18, 2021 15:20 UTC GP STRATEGIES CORP GPX · Entity 134545 Disposition to issuerCommon Stock 56,297 $20.85 $1,173,792.45
Disclosure

SEC source: 0000070415-21-000147 · wf-form4_163458482876899.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On July 15, 2021, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Learning Technologies Group plc, a public limited company incorporated in England and Wales ("LTG"), Learning Technologies Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of LTG ("US Holdco"), and Gravity Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of US Holdco ("Merger Sub"), pursuant to which each share of common stock of the Issuer was converted into the right to receive a cash payment equal to the per share merger consideration of $20.85.

F1 · price: On July 15, 2021, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Learning Technologies Group plc, a public limited company incorporated in England and Wales ("LTG"), Learning Technologies Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of LTG ("US Holdco"), and Gravity Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of US Holdco ("Merger Sub"), pursuant to which each share of common stock of the Issuer was converted into the right to receive a cash payment equal to the per share merger consideration of $20.85.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 13:53 UTC GP STRATEGIES CORP GPX · Entity 134545 GrantCommon Stock 544 $0.00 $0.00
Disclosure

SEC source: 0000070415-21-000119 · wf-form4_163336998467356.xml · nonDerivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,297

F1 · price: Represents a portion of the quarterly Director fees for the quarter ended September 30, 2021 paid in shares of the Registrant's Common Stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.